MIM
CRSP icon

Macroview Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Macroview Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$6.82K – 610
2024
Q1 		$6.82K Sell
100
-113
-53% -$8.09K 0.01% 354
2023
Q4 		$13.3K Buy
213
+113
+113% +$6.25K 0.02% 215
2023
Q3 		$4.54K Sell
100
-15
-13% -$775 0.01% 450
2023
Q2 		$6.46K Buy
115
+100
+667% +$5.67K 0.01% 312
2023
Q1 		$679 Hold
15
– – ﹤0.01% 396
2022
Q4 		$610 Hold
15
– – ﹤0.01% 412
2022
Q3 		$1K Hold
15
– – ﹤0.01% 364
2022
Q2 		$1K Hold
15
– – ﹤0.01% 390
2022
Q1 		$1K Buy
+15
New +$942 ﹤0.01% 374

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Macroview Investment Management's CRSP Position: Q2 2024 in Review

Macroview Investment Management sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 100 shares — an estimated $6.82K sold.

Macroview Investment Management first reported a position in CRSP in Q1 2022 and held it in 9 quarters. The position peaked at $13.3K in Q4 2023. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Macroview Investment Management reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macroview Investment Management sold 100 CRISPR Therapeutics shares in Q2 2024, an estimated $6.82K.
  • Macroview Investment Management first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 9 quarters.
  • Macroview Investment Management's CRISPR Therapeutics position peaked at $13.3K in Q4 2023.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Macroview Investment Management's 13F filing for Q2 2024, filed 23 Jul 2024.